MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.euo.2025.11.009

Медицинская библиотека · European urology oncology · 2026

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer.

Rozet François, Ruffion Alain, Lemercier Pablo, Soulié Michel, Robert Gregoire, Walz Jochen, De La Taille Alexandre, Salomon Laurent, Pfister Christian, Mathieu Romain, Vincendeau Sebastien, Descazaud Aurelien, Latorzeff Igor, Brureau Laurent, Colombel Marc, Rouprêt Morgan, Roca Lise, Pérez Christelle, Marion Sebastien, Barret Eric, Cathelineau Xavier, Fizazi Karim, Culine Stephane, GETUG-20 Investigators

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

Androgen-deprivation therapy survival benefits after radical prostatectomy (RP) in nonmetastatic high-risk prostate cancer (PCa) patients with an undetectable prostate-specific antigen (PSA) level are unclear. The AFU-GETUG-20 study assessed the benefit of leuprorelin immediately after RP in this population.

METHODS

This open-label, randomized, phase 3 trial is conducted at 37 French centers. Participants undergoing RP for nonmetastatic PCa were aged ≥18 yr, with a postoperative Gleason score of ≥7 and PSA <0.1 ng/ml. Participants were randomly assigned (1:1) to the observation or leuprorelin (45 mg subcutaneous Q6M, 24 mo) arm. The primary endpoint was metastasis-free survival in the intent-to-treat population (n = 322). The secondary objectives PSA and testosterone level evolution, PCa-specific survival, overall survival, safety, and quality of life.

KEY FINDINGS AND LIMITATIONS: From 2011 to 2017, 325 patients were randomized to the observation (n = 163) or leuprorelin (n = 162) arm. The 10-yr risk of metastasis occurrence was similar between arms (hazard ratio [HR] 0.63 [95% confidence interval {CI} 0.30-1.30]; p = 0.204) with no differences in PSA rise-free survival (HR 0.74 [95% CI 0.47-1.16]; p = 0.187), overall survival (HR 1.24 [95% CI 0.56-2.76]; p = 0.596), or PCa-specific survival (HR 0.57 [95% CI 0.10-3.17]; p = 0.512). Leuprorelin-treated patients had lower testosterone level after surgery (p < 0.001), shorter time to global health degradation (p = 0.0019), fatigue (p < 0.001), pain (p < 0.001), and additional adverse events, mainly hot flashes (83.6% vs 6.2%), pain (57.2% vs. 17.1%), fatigue (45.4% vs 16.3%), and psychiatric disorders (25.0% vs 2.3%). Insufficient enrollment affected the trial power but permitted pertinent comparison.

CONCLUSIONS AND CLINICAL IMPLICATIONS: Leuprorelin treatment immediately after RP in high-risk nonmetastatic PCa patients with an undetectable PSA level does not improve survival, but increases adverse events, leading to poorer quality of life compared with observation.

Для цитирования: Rozet François, Ruffion Alain, Lemercier Pablo, Soulié Michel, Robert Gregoire, Walz Jochen, De La Taille Alexandre, Salomon Laurent, Pfister Christian, Mathieu Romain, Vincendeau Sebastien, Descazaud Aurelien, Latorzeff Igor, Brureau Laurent, Colombel Marc, Rouprêt Morgan, Roca Lise, Pérez Christelle, Marion Sebastien, Barret Eric, Cathelineau Xavier, Fizazi Karim, Culine Stephane, GETUG-20 Investigators. Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer.. European urology oncology. 2026. DOI: 10.1016/j.euo.2025.11.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.